This trial will study an investigational drug, epcoritamab, to assess its effect on disease activity in people with a form of cancer called diffuse large B-cell lymphoma (DLBCL). 900 participants will be enrolled in 315 sites globally.
- Non-Hodgkin's Lymphoma
2 Primary · 5 Secondary · Reporting Duration: Up to Approximately 76 Months
2 Treatment Groups
Epcoritamab and R-CHOP
1 of 2
R-CHOP and Rituximab
1 of 2
900 Total Participants · 2 Treatment Groups
Primary Treatment: Epcoritamab and R-CHOP · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18 - 79 · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- 2023. "A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05578976.
Frequently Asked Questions
Does this research involve participants that are 20 or older?
"The age range that is able to enroll in this clinical trial, as specified by the eligibility criteria, is 18 to 79 years old." - Anonymous Online Contributor
How does the safety profile of R-CHOP and Rituximab compare to other similar treatments?
"The safety of R-CHOP and Rituximab was given a score of 3. This is based on the fact that this is a Phase 3 trial - meaning that there is efficacy data as well as multiple rounds of data in support of safety." - Anonymous Online Contributor
Is this research still enrolling new participants?
"The clinical trial in question is no longer looking for participants, as indicated by the fact that it was last updated over 8 months ago. However, there are 1807 other studies that are still recruiting patients." - Anonymous Online Contributor
Who meets the qualifications to participate in this clinical trial?
"This clinical trial is looking for 900 participants that have diffuse large b-cell lymphoma (dlbcl). The patients must be 18-79 years old and meet the following criteria: They must be planned to receive treatment with 6 cycles of standard rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) per investigator determination., DLBCL, Not Otherwise Specified (NOS)., High grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangement with" - Anonymous Online Contributor